Giuseppe Tonini
Giuseppe Tonini
Professore ordinario di Oncologia, Università Campus Bio-Medico di Roma
Dirección de correo verificada de unicampus.it
Título
Citado por
Citado por
Año
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective …
W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ...
The lancet oncology 11 (8), 753-762, 2010
21772010
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer
F Loupakis, C Cremolini, G Masi, S Lonardi, V Zagonel, L Salvatore, ...
New England Journal of Medicine 371 (17), 1609-1618, 2014
8322014
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular …
C Cremolini, F Loupakis, C Antoniotti, C Lupi, E Sensi, S Lonardi, S Mezi, ...
The Lancet Oncology 16 (13), 1306-1315, 2015
6892015
Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr)
E Cacciari, S Milani, A Balsamo, E Spada, G Bona, L Cavallo, F Cerutti, ...
Journal of endocrinological investigation 29 (7), 581-593, 2006
6442006
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F Loupakis, A Ruzzo, C Cremolini, B Vincenzi, L Salvatore, D Santini, ...
British journal of cancer 101 (4), 715-721, 2009
6082009
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial …
R Gralla, M Lichinitser, S Van Der Vegt, H Sleeboom, J Mezger, ...
Annals of Oncology 14 (10), 1570-1577, 2003
5842003
Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy …
P Maione, F Perrone, C Gallo, L Manzione, FV Piantedosi, S Barbera, ...
5002005
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer
F Loupakis, L Pollina, I Stasi, A Ruzzo, M Scartozzi, D Santini, G Masi, ...
Journal of clinical oncology 27 (16), 2622-2629, 2009
4862009
Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in …
D Santini, B Vincenzi, S Galluzzo, F Battistoni, L Rocci, O Venditti, ...
Clinical Cancer Research 13 (15), 4482-4486, 2007
4122007
Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients
D Santini, B Vincenzi, G Dicuonzo, G Avvisati, C Massacesi, F Battistoni, ...
Clinical Cancer Research 9 (8), 2893-2897, 2003
3972003
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ...
The lancet oncology 18 (12), 1688-1700, 2017
3762017
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
A Ruzzo, F Graziano, F Loupakis, E Rulli, E Canestrari, D Santini, ...
Journal of clinical oncology 25 (10), 1247-1254, 2007
3632007
Italian cross-sectional growth charts for height, weight and BMI (6–20 y)
E Cacciari, S Milani, A Balsamo, F Dammacco, F De Luca, F Chiarelli, ...
European journal of clinical nutrition 56 (2), 171-180, 2002
3392002
Pamidronate induces modifications of circulating angiogenetic factors in cancer patients
D Santini, B Vincenzi, G Avvisati, G Dicuonzo, F Battistoni, M Gavasci, ...
Clinical Cancer Research 8 (5), 1080-1084, 2002
3322002
High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice
D Santini, F Loupakis, B Vincenzi, I Floriani, I Stasi, E Canestrari, E Rulli, ...
The oncologist 13 (12), 1270-1275, 2008
2802008
Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB–IIA non-small cell lung cancer
TC Mineo, V Ambrogi, A Baldi, C Rabitti, P Bollero, B Vincenzi, G Tonini
Journal of clinical pathology 57 (6), 591-597, 2004
2792004
Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer
G Perrone, PA Ruffini, V Catalano, C Spino, D Santini, P Muretto, C Spoto, ...
European journal of cancer 44 (13), 1875-1882, 2008
2252008
The antineoplastic role of bisphosphonates: from basic research to clinical evidence
D Santini, UV Gentilucci, B Vincenzi, A Picardi, F Vasaturo, A La Cesa, ...
Annals of Oncology 14 (10), 1468-1476, 2003
2012003
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib
B Vincenzi, D Santini, A Russo, R Addeo, F Giuliani, L Montella, S Rizzo, ...
The oncologist 15 (1), 85, 2010
1952010
Gut microbiota and cancer: from pathogenesis to therapy
S Vivarelli, R Salemi, S Candido, L Falzone, M Santagati, S Stefani, ...
Cancers 11 (1), 38, 2019
1872019
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20